Latigo Biotherapeutics
Thousand Oaks, California, United States · Biotechnology · 40 employees
Latigo Biotherapeutics Inc., headquartered in Thousand Oaks, CA, is a privately held clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target the fundamental mechanism of pain transduction. The company’s proprietary, in-house technology generates novel drugs against targets validated by human genetics using the most advanced artificial intelligence, machi
Funding history
- Funding Round — $50.0M — Feb 2025
- Series series a — $135.0M — Feb 2024
Recent signals
- Mar 03, 2026: Latigo Biotherapeutics Appoints Neha Krishnamohan as Chief Financial Officer
- Feb 13, 2025: Raised $50.0M
- Aug 19, 2024: Latigo Biotherapeutics Appoints Neil Singla, M.D. as Chief Medical Officer
- Jul 22, 2024: Latigo Biotherapeutics Appoints Nima Farzan as Chief Executive Officer (CEO) to Lead Innovations in Pain Management
- Feb 14, 2024: Raised $135.0M in Series series a
See plans & pricing → Track Latigo Biotherapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.